Top-News
Werbung

Attraktive Knock-Outs auf Viatris

Typ Hebel Bid / Ask WKN
Call
4,3 2,24 € / 2,48 €
SW1KUL
Typ Hebel Bid / Ask WKN
Put
2,9 3,33 € / 3,57 €
SU5YP3
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Viatris
Pharmazeutika USA

Viatris News

Aktie
WKN:  A2QAME ISIN:  US92556V1061 US-Symbol:  VTRS
10,21 €
+0,115 €
+1,14%
10:48:06 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
1,21 Mrd.
Marktkapitalisierung *
12,22 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
S&P 500
IR-Website
zur Website
*Stand: 09.05.2023
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,50: ME7353

Viatris News

09.05.24 - PR Newswire
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges
Viatris Reports Strong First Quarter 2024 Financial Results and Reaffirms 2024 Financial Guidance Ranges PR Newswire
02.05.24 - PR Newswire
Viatris to Participate in the BofA Securities 2024 Health Care Conference
Viatris to Participate in the BofA Securities 2024 Health Care Conference PR Newswire
01.05.24 - PR Newswire
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health
Viatris Expands its Wellbeing Program with the Launch of Unmind, a Leading Workplace Resource Focused on Mental Health PR Newswire
16.04.24 - PR Newswire
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024
Viatris to Report First Quarter 2024 Financial Results on May 9, 2024 PR Newswire
15.04.24 - PR Newswire
Viatris Appoints Corinne Le Goff as Chief Commercial Officer
Viatris Appoints Corinne Le Goff as Chief Commercial Officer PR Newswire
01.04.24 - PR Newswire
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States
Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States PR Newswire
27.03.24 - PR Newswire
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline
Viatris Hosts R&D Event Focusing on its Collaboration with Idorsia, Phase 3 Assets Selatogrel and Cenerimod and Key Elements of its Pipeline PR Newswire
11.03.24 - PR Newswire
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a ...
07.03.24 - PR Newswire
Thinking about buying stock in Mirum Pharmaceuticals, Entera Bio, Andean Precious Metals, Viatris, or Biomx?
Thinking about buying stock in Mirum Pharmaceuticals, Entera Bio, Andean Precious Metals, Viatris, or Biomx? PR Newswire
28.02.24 - PR Newswire
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
Viatris Reports Fourth-​Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance PR Newswire
28.02.24 - PR Newswire
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration PR Newswire
05.02.24 - PR Newswire
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results
Viatris to Announce Fourth Quarter and Full-Year 2023 Financial Results PR Newswire
24.01.24 - wallstreet:online Zentralredaktion
"Gefährliche Ausmaße": David Einhorns Hedgefonds warnt Anleger & kündigt große geheime Aktienwette an!
Nach einer kurzen Pause ist David Einhorn von Greenlight Capital wieder am Aktienmarkt aktiv. Neben einer Warnung kündigt sein Hedgefonds auch eine geheimnisvolle Wette ...
19.01.24 - PR Newswire
Viatris recognised as a Top Employer 2024 in the UK for the second consecutive year
Viatris recognised as a Top Employer 2024 in the UK for the second consecutive year PR Newswire
21.12.23 - PR Newswire
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference
Viatris to Participate in 42nd Annual J.P. Morgan Healthcare Conference PR Newswire
15.12.23 - PR Newswire
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, and Philippe Martin as Chief R&D Officer
Viatris Continues its Preparations for Phase 2 of its Strategic Plan by Announcing the Appointment of Theodora "Doretta" Mistras as Chief Financial Officer, Effective March 1, 2024, ...
15.12.23 - PR Newswire
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders
Viatris Shareholders Re-elect All Nominated Directors and Approve All Voting Matters at Annual Meeting of Shareholders PR Newswire
14.11.23 - PR Newswire
Viatris to Participate in the Jefferies London Healthcare Conference
Viatris to Participate in the Jefferies London Healthcare Conference PR Newswire
13.11.23 - PR Newswire
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary ...
13.11.23 - PR Newswire
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary ...

Newssuche

Videos

17.05.24 +9,45%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »